

SeQuent Scientific Announces Q4 & FY19 Financial Results

FY19 Revenues at Rs.10,393 mn up by 22%, EBITDA at Rs.1,327 mn, up by 53%

FY19 PAT at Rs. 569 Mn, up 5.6x

Q4FY19 Revenues at Rs. 2,819 mn up by 21%, EBITDA at Rs.402 mn up by 31%

EPS at Rs. 2.0, Board recommends dividend of Rs. 0.2 per equity share (10%)

Mumbai, May 14, 2019

SeQuent Scientific Limited (SeQuent), which has businesses across Animal Health (Alivira) & Analytical Services today announced its financial results for the fourth quarter and full year ended March 31, 2019.

Consolidated Financial Highlights

Rs. in millions

	FY19	FY18	Growth (%)	Q4FY19	Q4FY18	Growth (%)
Revenues	10,393	8,494	22.4%	2,819	2,328	21.1%
EBITDA	1,327	871	52.5%	402	308	30.9%
EBITDA %	12.8%	10.3%		14.3%	13.2%	
PAT	569	102	5.6x	213	84	2.5x
Net margin %	5.5%	1.2%		7.6%	3.6%	

Detailed presentation on the performance forms part of this press release.

Commenting on the Company's performance, **Manish Gupta, Managing Director** stated "This has been a year of strong performance wherein our Revenue and EBITDA grew by 22% and 52% respectively, with a 250 bps margin improvement and a 5.6x growth in PAT. The all-round growth was fueled by execution excellence across both APIs and formulations.

We have significantly scaled up our capabilities during FY19 with the addition of an injectable manufacturing facility in EU, expanding our formulations R&D capabilities and commercialisation of two products in US from our API facility in Vizag.

With the twin levers of scale and operating efficiencies playing out, our return ratios have improved resulting in robust operational cashflow. This reflects in the upward revision of credit rating during the year to **A-**. With a differentiated strategy, favourable environment and all the building blocks in place, we are well on course to create sustainable value for our stakeholders."

Earnings Call with Investors

The Company will conduct an Earnings call at **4:00 PM IST on May 14, 2019** where the Management will discuss the Company's performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time. The dial-in numbers for this call are **+91 22 6280 1263 or +91 22 7115 8213**.

About SeQuent Scientific Limited

SeQuent Scientific Limited (BSE-512529, NSE-SEQUENT) headquartered in Mumbai, India with a global footprint, operates in the domains of Animal Health (Alivira) and Analytical Services. SeQuent has eight manufacturing facilities based in India, Spain, Germany, Brazil and Turkey with approvals from global regulatory bodies including USFDA, EUGMP, WHO, TGA among others. Its API facility at Vizag is India's first and only USFDA approved facility for veterinary APIs.

For details, feel free to contact:

Tushar Mistry

Chief Financial Officer

Tel: +91 22 4111 4717

tushar.m@sequent.in

Shivangi Bubna

Christensen Investor Relations

Tel : +91 22 4215 0210

sbubna@christensenir.com

Registered Office

301/A, 'Dosti Pinnacle', Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Maharashtra, India

CIN: L99999MH1985PLC036685

BSE Code:512529 | NSE: SEQUENT

ISIN: INE807F01027 | REUTERS: EQU.BO

Website: www.sequent.in

Abhishek Singhal

Investor Relations Consultants

abhishek.s@sequent.in

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.